Follicular Lymphoma Drugs Market Size, Share, and Industry Analysis, By Type (Anti-CD20 mAbs, Chemotherapy Agents, Kinase Inhibitor, and Others) By Administration Route (Oral and Injection), Regional Forecast To 2031

Updated On: 08 April 2024

FOLLICULAR LYMPHOMA DRUGS MARKET REPORT OVERVIEW

• 
• Request Free Sample PDF to learn more about this report

The global follicular lymphoma drugs market size was USD 1848.5 million in 2022 and market is projected to touch USD 3514.4 million by 2031, at a CAGR of 7.4%.

The global COVID-19 pandemic has been unprecedented and staggering, with it experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels.

Follicular lymphoma is a tumor that disturbs white blood cells called lymphocytes. There are two types of lymphomas: Hodgkin's and non-Hodgkin's, built on the kind of white blood cell they move. Follicular lymphoma is a non-Hodgkin's lymphoma. Drugs for Follicular lymphoma are Anti-CD20 mAbs, Kinase Inhibitor, Chemotherapy Agents. Increasing incidence of follicular lymphoma globally and growing necessity for better and more progressive cure for the illness are amongst the main aspects motivating the global market growth.

COVID-19 Impact: Increasing Demand for Product to Fuel Market Progress 

COVID-19 steered in a different age for telehealth, medical strategies, blood transport bags and boxes and remote observing.  While the far-reaching effects of COVID-19 have presented the world to a “new normal,” the highest influence has been in medical devices. Moreover, the demand for blood bags and equipment has increased throughout COVID-19, following the pandemic. Moreover, R&D activities have come into attention. All the government activities and healthcare companies have come onward to backing the expansion of diagnostics and treatment techniques for COVID-19.

LATEST TRENDS

"Growing demand for Cancer Treatments to Incite Market Growth"

Follicular lymphoma drugs can be cured on the basis of the sensitivity of related indications and on cancer growth rate. Though, radiation only can be used for the action of follicular lymphoma in maximum cases. In more progressive cases chemotherapy or a monoclonal antibody rituximab, only or the grouping of both are used for the dealing of follicular lymphoma. Radiation and chemotherapy are currently the approachable action for follicular lymphoma. Furthermore, monoclonal antibodies are more leading over the chemotherapy, as they act straight by directing on cancer cells and thus, upsurges immune cells that destructs cancer, which upsurges reply to the cure.

"Various Treatments to Stimulate Market Expansion "

Treatment of follicular lymphoma reversion or development is influenced by the period of reduction with earlier treatments. For patients with decline or development on first-line cure who have an extensive period of reduction, choices can contain chemoimmunotherapy followed by rituximab maintenance.The National Comprehensive Cancer Network guidelines reference numerous choices for patients with follicular lymphoma in second-line and following therapy, counting lenalidomide plus rituximab, or lenalidomide plus obinutuzumab, or the EZH2 inhibitor, tazemetostat. There are also nearly chemotherapy selections stated in the recommendations, like R-CVP [rituximab, cyclophosphamide, vincristine, prednisone], bendamustine plus rituximab or obinotuzumab, or R-CHOP [rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone].

FOLLICULAR LYMPHOMA DRUGS MARKET SEGMENTATION

• 
• Request Free Sample PDF to learn more about this report

• By Type

Based on type, the market is divided into Anti-CD20 mAbs, Chemotherapy Agents, Kinase Inhibitor, and Others.

• By Application

Based on the application, the market is divided into Oral and Injection.

DRIVING FACTORS

"R&D Activities to Expand Market Growth"

Key features backing the global follicular lymphoma drugs market development are increasing occurrence of follicular lymphoma worldwide, increasing incidence of blood syndromes, growing alertness of blood tumor, and growing R&D activities for fresher and more progressive medicines and treatment techniques for the disease. For instance, in June 2020, the U.S. FDA accepted the Tazemetostat medicine for conduct of reverted or refractory follicular lymphoma in grown-ups.

Increasing awareness of initial analysis and dealing of numerous blood tumors, growing use of monoclonal antibodies in follicular lymphoma treatment, upsurge in government advantages towards progressive cancer organization, and growing governing supports for novel and gifted pipeline medicines are among the other main aspects anticipated to enhance the global follicular lymphoma drugs market growth in the coming years.

RESTRAINING FACTORS

"Early Stages of the Treatment to Restrict Market Growth"

The treatment for follicular lymphoma has shown some tremendous results in recent years. However, the strategies are still unclear and in the research stage which is anticipated to impede the market advancement in coming years.

FOLLICULAR LYMPHOMA DRUGS MARKET REGIONAL INSIGHTS

• 

• Request Free Sample PDF to learn more about this report

"R&D Activities to Foster Growth in North America"

North America is predicted to account for the largest follicular lymphoma drugs market share. This is owing to the upsurge in the occurrence of follicular lymphoma, rise in R&D activities for the invention of fresher drugs, and an upsurge in healthcare spending in the region.

Asia Pacific follicular lymphoma drugs market has a profitable development due to the huge patient group, upsurge in awareness about lymphoma treatment, and government introductions for the hindrance of cancer are projected to fuel the market in the region. 

Europe follicular lymphoma drugs market is projected to mature considerably owing to the approval of novel treatments, cultured healthcare frame, a rise in the occurrence of follicular lymphoma owing to modification in routine in the region.

KEY INDUSTRY PLAYERS

"Leading Players Adopt New Strategies to Stay Competitive"

The report covers information about the list of market players and their latest development in the industry. The information includes mergers, partnerships, acquisitions, technological developments, and production lines. Other aspects examined for this market include complete research on companies producing and introducing the latest products, regions they conduct their operations in, automation, technology adoption, generating the most revenue, and making a difference with their products.

List of Market Players Profiled

• Roche (Switzerland)
• Gilead Sciences (U.S.)
• TG Therapeutics (U.S.)
• Bayer (Germany)
• Secura Bio (U.S.)
• Epizymes (U.S.)
• Eisai (Japan)
• Acrotech Biopharma (U.S.)
• Teva (Israel)
• Eagle Pharmaceuticals (U.S.)
• MundiPharma (U.K.)

REPORT COVERAGE

This research profiles a report with general studies that explain the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by examining the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, restraints, and others. This analysis is subject to alteration if the key players and probable analysis of market dynamics change.